Myriad presents new myRisk hereditary cancer data at 2015 ASCO Annual Meeting

SALT LAKE CITY, Utah, May 29, 2015 - Myriad Genetics, Inc. (NASDAQ: MYGN) today announced it will highlight several new clinical studies on its myRisk Hereditary Cancer molecular diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill. The myRisk Hereditary Cancer test assesses 25 genes for mutations associated with eight hereditary cancers. Finding deleterious mutations in these genes can help patients with cancer receive appropriate medical care and reduce the risk of second cancers, while patients without cancer can take steps in consultation with their healthcare provider to lower their risk of developing cancer. "Myriad is pioneering a new era of cancer treatment and prevention. The myRisk Hereditary Cancer test has the potential to reduce the burden of hereditary cancer in the lives of women and men for generations to come," said Richard Wenstrup, M.D., chief medical officer, Myriad. "myRisk represents a significant new opportunity to help physicians tailor treatment to individuals based on their genetic results as well as their personal and family history of cancer." Below are the key myRisk Hereditary Cancer presentations being highlighted at #ASCO15.

BREAST CANCER Podium Presentation S100BC: Predisposing Germline Mutations in High Grade ER+HER2- Breast Cancer Patients Diagnosed END